Literature DB >> 32248635

Interactions between ocular and systemic disease using national register-based data in the Danish Excellence Centre in Ophthalmic Epidemiology (DECODE-EYE): study perspective.

Jakob Grauslund1,2,3, Lonny Stokholm2,4, Kirsten Ohm Kyvik2, Morten Dornonville de la Cour5,6, Line Kessel5,6, Katrine Hass Rubin2,4.   

Abstract

PURPOSE: The Danish Excellence Centre in Ophthalmic Epidemiology (DECODE-EYE) is a national research collaboration formed in order to study the real-life interaction between ocular and systemic disease based on the entire Danish population. Here, we aim to describe the study design and the methodology, which will be used.
METHODS: We will extract data from various healthcare registers and databases including the Danish Civil Registration System (unique personal identifier), the Danish National Patient Register (inpatient and outpatient visits), the Danish National Prescription Registry (redeemed prescription drugs), the National Health Service Register (data on health services in primary health care), the Danish Register of Cause of Death (data on cause of death), Statistics Denmark (demographic and socioeconomic data), the Danish Registry of Diabetic Retinopathy (level of diabetic retinopathy (DR) in diabetes patients) and the database of the Danish Association of the Blind (date and cause of blindness). Relevant registers will be linked by the unique personal identifier, and associations will be examined cross-sectional and/or longitudinally, in principle in 1:5 age- and gender-matched case-control cohort studies.
CONCLUSION: Denmark has a strong tradition in register-based healthcare research, given a high number of validated national registers and databases. DECODE-EYE will provide Danish, large-scale data on associations between ocular and systemic disease. With a target population of 5.8 million individuals, twelve separate studies (Protocols A-L) have initially been designed to be studied in the upcoming years. These will provide novel data on interactions between systemic disease and relevant ophthalmological end-points like blindness, DR, glaucoma, corneal disease, retinal vascular disease, cataract and intravitreal angiostatic treatment.
© 2020 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  nationwide; ocular; ophthalmology; population health; real life; register data; systemic

Mesh:

Year:  2020        PMID: 32248635     DOI: 10.1111/aos.14415

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  3 in total

1.  Investigation of the correlation between diabetic retinopathy and prevalent and incident migraine in a national cohort study.

Authors:  Anna Stage Vergmann; Lonny Stokholm; Katrine Hass Rubin; Anne Thykjær; Sören Möller; Caroline Schmidt Laugesen; Steffen Heegaard; Kurt Højlund; Ryo Kawasaki; Katja Christina Schielke; Jakob Grauslund
Journal:  Sci Rep       Date:  2022-07-20       Impact factor: 4.996

2.  Inverse Cross-sectional and Longitudinal Relationships between Diabetic Retinopathy and Obstructive Sleep Apnea in Type 2 Diabetes: Results from a National Screening Program.

Authors:  Jakob Grauslund; Lonny Stokholm; Anne S Thykjær; Sören Möller; Caroline S Laugesen; Jens Andresen; Toke Bek; Morten la Cour; Steffen Heegaard; Kurt Højlund; Ryo Kawasaki; Javad Hajari; Kirsten O Kyvik; Katja C Schielke; Katrine H Rubin; Malin L Rasmussen
Journal:  Ophthalmol Sci       Date:  2021-03-12

3.  Diabetic Retinopathy Predicts Risk of Alzheimer's Disease: A Danish Registry-Based Nationwide Cohort Study.

Authors:  Frederik Nørregaard Pedersen; Lonny Stokholm; Frans Pouwer; Katrine Hass Rubin; Tunde Peto; Ulrik Frydkjær-Olsen; Anne Suhr Thykjær; Nis Andersen; Jens Andresen; Toke Bek; Morten La Cour; Steffen Heegaard; Kurt Højlund; Ryo Kawasaki; Javad Nouri Hajari; Kirsten Ohm Kyvik; Caroline Schmidt Laugesen; Katja Christina Schielke; Rafael Simó; Jakob Grauslund
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.